Previous 10 | Next 10 |
RESEARCH TRIANGLE PARK, N.C., April 11, 2022 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will present at the 21 st Annual Needham Virtual Healthcare Conference on Thursday, April 14, 2022, at 11:45 a.m. ET. Links to a...
On 04/08/2022, BioCryst held an unplanned fire sale. BCX9930 is more than a random phase 2 asset; it is a material component of BioCryst's value. BioCryst has the firepower to wait out developments but it may be costly for shareholders. For further details see: BioCryst:...
BCRX halted enrollment in 3 trials of BCX9930 following elevated serum creatine in some patients, which indicates kidney impairment. While Orladeyo is doing very well, BCX9930 was BioCryst's pipeline future. With strong competition from Novartis and soliris biosims, BCX9930's pros...
With investors worried about a murky economic future, the major U.S. equity averages posted a mixed performance on Friday. Weakness in tech drove the Nasdaq and S&P 500 lower, while the Dow scratched out a modest gain. Semiconductor makers contributed to the slide in technology, with Trui...
Gainers: MedAvail (MDVL) +72%. Lyra Therapeutics (LYRA) +31%. TSR (TSRI) +24%. Biofrontera (BFRI) +18%. Takung Art (TKAT) +16%. Akanda (AKAN) +15%. Mullen Automotive (MULN) +16%. Nurix Therapeutics (NRIX) +14%. Borr Drilling (BORR) +14%. EPAM Systems (EPAM) +13%. Losers: Kaleid...
Shares of BioCryst Pharmaceuticals (NASDAQ: BCRX) were crashing 32.9% lower as of 10:38 a.m. ET on Friday. The steep decline came after the company announced that it has paused enrollment in three clinical studies evaluating experimental drug BCX9930. BioCryst stated in a press ...
Gainers: MedAvail MDVL +61%. Lyra Therapeutics LYRA +27%. Medicenna Therapeutics (MDNA) +25%. Biofrontera BFRI +23%. IsoPlexis (ISO) +8%. Losers: BioCryst Pharmaceuticals BCRX -33%. Sunshine Biopharma SBFM -33%. Werewolf Therapeutics (HOWL) -15%. I...
The shares of BioCryst Pharmaceuticals (NASDAQ:BCRX) have lost ~22% in the pre-market Friday after the commercial-stage biotech announced its decision to pause enrollment in clinical studies involving BCX9930, an oral factor D inhibitor targeted at complement-mediated diseases. The ...
RESEARCH TRIANGLE PARK, N.C., April 08, 2022 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company has paused enrollment in clinical trials with BCX9930 while the company investigates elevated serum creatinine levels seen in some patient...
Baker Brothers’ 13F portfolio value decreased from $22.77B to $20.55B this quarter. Incyte and Legend Biotech stakes were increased this quarter. The top three positions are Seagen, BeiGene, and Incyte Corporation and they add up to almost ~63% of the portfolio. For f...
News, Short Squeeze, Breakout and More Instantly...
BioCryst Pharmaceuticals Inc. Company Name:
BCRX Stock Symbol:
NASDAQ Market:
BioCryst Pharmaceuticals Inc. Website:
RESEARCH TRIANGLE PARK, N.C., July 09, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the General Directorate of Medicines, Supplies and Drugs (DIGEMID) in Peru has granted approval for oral, once-daily ORLADEYO ® (berotralstat) for t...
2024-06-27 04:12:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-06-07 10:20:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...